Loading
An experimental drug that uses an antibody to deliver a cancer-killing drug and an immune activator to cells carrying TROP2. An early human study is recruiting; benefit and safety are still being tested.
ASP2998 is Astellas's TROP2-targeted immunostimulatory dual-payload ADC, discovered through collaborative research with Sutro Biopharma. The phase 1b/2 first-in-human study NCT07287995 evaluates monotherapy and tumor-specific combinations. The registry, last updated 2 September 2026 and checked 6 October, lists recruiting status, an actual start on 5 February 2026 and estimated enrollment of 428. The earlier ASCO 2026 trial-in-progress abstract planned 196 participants; it is not an efficacy readout. No results are posted in the registry. Astellas lists the program in phase 1; the registered phase 1/2 design does not establish completion of phase 1 or demonstrated efficacy.
TROP2-directed antibody carrying a cytotoxic topoisomerase I inhibitor and a STING immune agonist. This is an immunostimulatory dual-payload ADC, rather than two cytotoxic payloads. Connects to TROP2.
1.ASP2998's antibody arm binds TROP2 on the surface of the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ASP2998" OR ABSTRACT:"ASP2998") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ASP2998, not a curated reading list.
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC) and the tags pipeline, dual-payload.
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Astellas, Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/